A Phase 1 interventional study of MDV3100 in Prostate Cancer, sponsored by Pfizer. Completed at 3 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-22.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 100th largest by enrollment, is one of 5 that started in 2012, is one of 22 in phase 1, and was the 9th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
42 studies in Prostatic Neoplasms by Pfizer: 3 open now, 8 under way, 5 of them phase 3. Of 33 finished, 28 (85%) have results posted.
Among the 42 studies in Prostatic Neoplasms by Pfizer, this one is the 30th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2012, is one of 8 in phase 1, and was the 14th registered.
Pfizer’s Prostatic Neoplasms studies by the year they started, since 1998.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
Among Pfizer’s 42 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety of MDV3100 given in combination with Docetaxel in men with advanced prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MDV3100
4 x 40 mg capsules, orally, once per day
Percentage of Participants Who Required Study Drug Dose Reduction During Treatment Periods 1 and 2
Percentage of participants that required dose reductions of Docetaxel and Enzalutamide treatment were reported in this outcome measure. Dose modifications (interruptions or dose reductions) were permitted for participants who had adverse events that were intolerable or could not be improved by other means. Dose reductions or delays were determined according to the prescribing information and at the discretion of the investigator.
Time frame: Treatment Period 1 (Day 1) up to end of Treatment Period 2 (42 days)
Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)
AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Percentage of participants that discontinued study drug due to adverse events were reported in this outcome measure.
Time frame: Treatment Period 1 (Day 1) up to end of study treatment (maximum 70 months)
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Criteria:1)systolic blood pressure (SBP):a) absolute result(AR)\>=180millimeters of mercury(mmHg) and increase from baseline(BL)greater than(\>)40mmHg,b)less than(\<)90mmHg and decrease from BL\>30mmHg,c)most extreme post-BL result\>=140mmHg,d)most extreme post-BL result\>=180mmHg,e)most extreme result(MER)\>=180mmHg and \>=20mmHg change from BL,f)MER\>=140mmHg and \>=20mmHg change from BL;2)diastolic blood pressure(DBP):a)AR\>105mmHg and increase from BL,b)AR\<50mmHg and decrease from BL\>20mmHg;c)most extreme post-BL result\>=90mmHg,d)MER\>=90mmHg and \>=15mmHg change from BL,e)most extreme post-BL result\>=105mmHg,f)MER\>=105mmHg and\>=15mmHg change from BL;3)heart rate:a)AR\>120 beats per minute(bpm) and increase from BL\>30bpm,b) AR\<50 bpm and decrease from BL\>20bpm.Only those categories in which at least 1 participant had clinically significant vital sign abnormality, were reported in this outcome measure.T1 = Timeframe for "Combination Therapy" and T2 = Time frame for "Post-Docetaxel Enzalutamide".
Time frame: T1= Baseline (Day 1) up to a maximum of approximately Month 12; T2 = From Month 10.6 up to a maximum of approximately Month 71.5
Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECG)
Clinically significant changes from baseline in ECG findings was based up on investigator's discretion. T1 = Timeframe for "Combination Therapy: Docetaxel 75 mg/m\^2+ Enzalutamide 160 mg" and T2 = Time frame for "Post-Docetaxel Enzalutamide 160 mg".
Time frame: T1= Baseline (Day 1) up to a maximum of approximately Month 12; T2 = From Month 10.6 up to a maximum of approximately Month 71.5
Maximum Plasma Concentration (Cmax) of Docetaxel With and Without Enzalutamide Treatment
Time frame: Docetaxel without Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 1; Docetaxel with Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 2
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Docetaxel With and Without Enzalutamide Treatment
AUClast was observed using a linear mixed-effects model.
Time frame: Docetaxel without Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 1; Docetaxel with Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 2
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of Docetaxel With and Without Enzalutamide Treatment
AUCinf was observed using a linear mixed-effects model.
Time frame: Docetaxel without Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 1; Docetaxel with Enzalutamide: Predose, 0.5, 1, 1.5, 2, 4, 8 and 24 hour post docetaxel infusion on Day 1 of Treatment Period 2
| Milestone | Docetaxel 75 mg/m^2+ Enzalutamide 160 mg |
|---|---|
| Started | 22 |
| Completed | 0 |
| Not completed | 22 |
| Withdrew: Adverse event | 3 |
| Withdrew: Other | 3 |
| Withdrew: Progressive disease | 13 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Death | 2 |
Percentage of participants that required dose reductions of Docetaxel and Enzalutamide treatment were reported in this outcome measure. Dose modifications (interruptions or dose reductions) were permitted for participants who had adverse events that were intolerable or could not be improved by other means. Dose reductions or delays were determined according to the prescribing information and at the discretion of the investigator.
| percentage of participants | Combination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg |
|---|---|
| Docetaxel Dose Reductions | 4.5 |
| Enzalutamide Dose Reductions | 0.0 |
AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Percentage of participants that discontinued study drug due to adverse events were reported in this outcome measure.
| percentage of participants | Docetaxel 75 mg/m^2+ Enzalutamide 160 mg |
|---|---|
| Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE) | 9.1 |
Criteria:1)systolic blood pressure (SBP):a) absolute result(AR)\>=180millimeters of mercury(mmHg) and increase from baseline(BL)greater than(\>)40mmHg,b)less than(\<)90mmHg and decrease from BL\>30mmHg,c)most extreme post-BL result\>=140mmHg,d)most extreme post-BL result\>=180mmHg,e)most extreme result(MER)\>=180mmHg and \>=20mmHg change from BL,f)MER\>=140mmHg and \>=20mmHg change from BL;2)diastolic blood pressure(DBP):a)AR\>105mmHg and increase from BL,b)AR\<50mmHg and decrease from BL\>20mmHg;c)most extreme post-BL result\>=90mmHg,d)MER\>=90mmHg and \>=15mmHg change from BL,e)most extreme post-BL result\>=105mmHg,f)MER\>=105mmHg and\>=15mmHg change from BL;3)heart rate:a)AR\>120 beats per minute(bpm) and increase from BL\>30bpm,b) AR\<50 bpm and decrease from BL\>20bpm.Only those categories in which at least 1 participant had clinically significant vital sign abnormality, were reported in this outcome measure.T1 = Timeframe for "Combination Therapy" and T2 = Time frame for "Post-Docetaxel Enzalutamide".
| Participants | Combination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg | Post-Docetaxel Enzalutamide 160 mg |
|---|---|---|
| SBP: AR- > 180 mmHg, increase from BL > 40 mmHg | 0 | 1 |
| SBP: AR- < 90 mmHg, decrease from BL > 30 mmHg | 1 | 0 |
| SBP: Most extreme post- BL result >= 140 mmHg | 10 | 7 |
| SBP: Most extreme post- BL result >= 180 mmHg | 0 | 2 |
| SBP: MER >= 180 mmHg, >= 20 mmHg change from BL | 0 | 2 |
| SBP: MER >= 140 mmHg, >= 20 mmHg change from BL | 5 | 5 |
| DBP: Most extreme post-BL result >= 90 mmHg | 3 | 6 |
| DBP: Most extreme post-BL result >= 105 mmHg | 0 | 1 |
| DBP: MER >= 105 mmHg,>= 15 mmHg change from BL | 0 | 1 |
| DBP: MER >= 90 mmHg,>= 15 mmHg change from BL | 1 | 4 |
| Heart Rate: AR >120 bpm, increase from BL >30 bpm | 0 | 1 |
| Heart Rate: AR <50 bpm, decrease from BL >30 bpm | 0 | 1 |
Clinically significant changes from baseline in ECG findings was based up on investigator's discretion. T1 = Timeframe for "Combination Therapy: Docetaxel 75 mg/m\^2+ Enzalutamide 160 mg" and T2 = Time frame for "Post-Docetaxel Enzalutamide 160 mg".
| Participants | Combination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg | Post-Docetaxel Enzalutamide 160 mg |
|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECG) | 1 | 0 |
| nanograms per milliliter | Combination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg |
|---|---|
| Docetaxel Without Enzalutamide | 1722.1 ± 27.14 |
| Docetaxel With Enzalutamide | 1662.9 ± 23.00 |
AUClast was observed using a linear mixed-effects model.
| nanograms*hour per milliliter | Combination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg |
|---|---|
| Docetaxel Without Enzalutamide | 1866.6 ± 29.05 |
| Docetaxel With Enzalutamide | 1674.4 ± 19.32 |
AUCinf was observed using a linear mixed-effects model.
| nanograms*hour per milliliter | Combination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg |
|---|---|
| Docetaxel Without Enzalutamide | 2020.1 ± 27.98 |
| Docetaxel With Enzalutamide | 1769.1 ± 18.91 |
Collected over Baseline up to a maximum of approximately Month 12 for Combination Therapy; From Month 10.6 up to a maximum of approximately Month 71.5 for Post-Docetaxel Enzalutamide. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg | — | 8/22 (36.4%) | 21/22 (95.5%) |
| Post-Docetaxel Enzalutamide 160 mg | — | 7/21 (33.3%) | 18/21 (85.7%) |
| Event | Combination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg | Post-Docetaxel Enzalutamide 160 mg |
|---|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 0/22 | 3/21 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 3/22 | 0/21 |
| ACUTE CORONARY SYNDROMECardiac disorders | 2/22 | 0/21 |
| ATRIAL FLUTTERCardiac disorders | 0/22 | 1/21 |
| CARDIAC FAILURE ACUTECardiac disorders | 0/22 | 1/21 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 0/22 | 1/21 |
| ASTHENIAGeneral disorders | 0/22 | 1/21 |
| IMPAIRED HEALINGGeneral disorders | 0/22 | 1/21 |
| PYREXIAGeneral disorders | 1/22 | 1/21 |
| CELLULITISInfections and infestations | 0/22 | 1/21 |
| Event | Combination Therapy: Docetaxel 75 mg/m^2+ Enzalutamide 160 mg | Post-Docetaxel Enzalutamide 160 mg |
|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 19/22 | 1/21 |
| FATIGUEGeneral disorders | 16/22 | 5/21 |
| NEUROPATHY PERIPHERALNervous system disorders | 10/22 | 1/21 |
| CONSTIPATIONGastrointestinal disorders | 7/22 | 9/21 |
| NAUSEAGastrointestinal disorders | 9/22 | 1/21 |
| BACK PAINMusculoskeletal and connective tissue disorders | 8/22 | 5/21 |
| PERIPHERAL SENSORY NEUROPATHYNervous system disorders | 7/22 | 4/21 |
| DECREASED APPETITEMetabolism and nutrition disorders | 5/22 | 6/21 |
| DIARRHOEAGastrointestinal disorders | 6/22 | 0/21 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 6/22 | 4/21 |
Intent-to-treat (ITT) population included all enrolled participants.
| Age, Continuous(years) | Docetaxel 75 mg/m^2+ Enzalutamide 160 mg |
|---|---|
| Mean | 68.0 ± 10.66 |
| Sex: Female, Male(Participants) | Docetaxel 75 mg/m^2+ Enzalutamide 160 mg |
|---|---|
| Female | 0 |
| Male | 22 |
| Ethnicity (NIH/OMB)(Participants) | Docetaxel 75 mg/m^2+ Enzalutamide 160 mg |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 22 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Docetaxel 75 mg/m^2+ Enzalutamide 160 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 19 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
No publications or documents are linked to this record.
Ran from Jan 2012 to primary completion in Jul 2013, 17 months.
Results were first posted in Apr 2019, 5 years 9 months after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 17 months is below that.
Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide